NCT07602569 A Prospective Study on the Diagnosis of Malignant Tumors With 18F-FGIn PET/CT
| NCT ID | NCT07602569 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Affiliated Cancer Hospital & Institute of Guangzhou Medical University |
| Condition | Cancer (With or Without Metastasis) |
| Study Type | OBSERVATIONAL |
| Enrollment | 110 participants |
| Start Date | 2025-10-20 |
| Primary Completion | 2028-08-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 110 participants in total. It began in 2025-10-20 with a primary completion date of 2028-08-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Glutamine is a crucial nutrient for cancer cell growth, and its metabolism is frequently dysregulated in malignancies. 18F-FGln is a PET tracer that targets this altered glutamine metabolism. However, there are currently limited studies on the diagnostic value of 18F-FGln PET/CT in various types of cancer. Therefore, this prospective study was conducted to investigate the value of 18F-FGln PET/CT in patients with various types of malignant tumors.
Eligibility Criteria
Inclusion Criteria: 1. Patients with clinical suspicion or exclusion of primary or recurrent malignant tumors (such as glioma of the brain, liver cancer, gastric cancer, duodenal cancer, colorectal cancer, ovarian cancer, etc., where 18F-FDG is prone to false negatives and false positives) 2. Patients undergoing tumor staging or evaluating treatment effect using 18F-FDG PET/CT or 18F-FGln PET/CT to determine the most appropriate treatment strategy 3. Patients without other tumor history 4. Patients with good compliance, providing informed consent, and able to follow the research protocol Exclusion Criteria: 1. pregnant or lactating patients or patients under 18 years old 2. the subjects and their parents or legal representatives are unable or unwilling to provide written informed consent; 3. patients with poor compliance, unable to tolerate or cooperate with PET/CT examinations. 4. those who have undergone gastrointestinal barium meal examination within one week; 5. other situations where the investigators consider it inappropriate for the subjects to participate in this clinical trial
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07602569 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Cancer (With or Without Metastasis). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07602569 currently recruiting?
Yes, NCT07602569 is actively recruiting participants. Contact the research team at zhangrusen2015@163.com for enrollment information.
Where is the NCT07602569 trial being conducted?
This trial is being conducted at Guangzhou, China.
Who is sponsoring the NCT07602569 clinical trial?
NCT07602569 is sponsored by Affiliated Cancer Hospital & Institute of Guangzhou Medical University. The trial plans to enroll 110 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.